Nicole Barna - 19 Jan 2023 Form 4 Insider Report for Codiak BioSciences, Inc.

Role
Senior Vice President, Human Resources
Signature
/s/ Yalonda Howze, Attorney-in-Fact for Nicole Barna
Issuer symbol
N/A
Transactions as of
19 Jan 2023
Net transactions value
-$481
Form type
4
Filing time
23 Jan 2023, 15:32:33 UTC
Previous filing
20 Sep 2022
Next filing
26 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise +2,167 +32% 8,948 19 Jan 2023 Direct F1
transaction CDAKQ Common Stock Sale $481 -836 -9.3% $0.5750* 8,112 20 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Restricted Stock Units Options Exercise $0 -2,167 -33% $0.000000 4,333 19 Jan 2023 Common Stock 2,167 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
F3 Each RSU represents a contingent right to receive one share of common stock.
F4 On January 19, 2022, the reporting person was granted 6,500 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Senior Vice President, Human Resources